Oral GLP-1 market valued at $6.8 billion and climbing fast

A new industry analysis values the global oral GLP-1 receptor agonist weight-loss drug market at $6.8 billion in 2025, with growth projected at a compound annual rate of 38.2% through 2034, reaching an estimated $92.4 billion ^[1]. The forecast covers a market that did not exist in pill form for weight loss until recently: within four months, two oral GLP-1 products for obesity went from unapproved to on pharmacy shelves in the United States ^[2].

The first was oral Wegovy, Novo Nordisk's once-daily 25 mg semaglutide tablet, approved by the FDA on December 22, 2025. In the OASIS 4 trial, adherent participants lost about 16.6% of body weight, a result the company says is comparable to the injectable version ^[2]. The second was Eli Lilly's Foundayo (orforglipron), approved April 1, 2026, for adults with obesity or overweight with a weight-related condition. Unlike oral Wegovy, Foundayo has no food or water timing restrictions. In the ATTAIN-1 trial, participants lost up to about 12.4% of body weight at 72 weeks ^[2].

Market researchers attribute the surge partly to that formulation shift. North America accounted for 44.5% of 2025 revenue, about $3.03 billion, with the report citing high obesity and diabetes rates, insurance coverage, and telehealth prescribing as drivers ^[1]. "Small molecule non-peptide" products, the category Foundayo belongs to, held the largest share of the market type breakdown at 42.3% in 2025 ^[1]. The same report notes that real-world adherence data for injectable GLP-1 therapies shows roughly 30-40% of patients discontinue within six months, with injection aversion cited as the leading reason — a pattern the industry is betting oral options will change ^[1].

Why it matters for patients

For people weighing GLP-1 treatment, the growth of oral options changes the practical calculus but not necessarily the effectiveness ranking. Head-to-head data continue to show injectable tirzepatide (Zepbound) outperforming semaglutide: in the SURMOUNT-5 trial, tirzepatide produced 20.2% average weight loss versus 13.7% for semaglutide over 72 weeks ^[2]. Foundayo, the newest oral entrant, is the least potent of the major approved options at about 12.4% ^[2], while oral Wegovy's 16.6% figure roughly matches its injectable counterpart rather than exceeding it ^[2].

That means the new pills mainly address convenience and comfort, not a step up in weight-loss power. Patients who have avoided injections may now have an approved, pill-based path into GLP-1 therapy, but they should not expect the tablets to outperform the strongest injectable options already on the market. Pricing, insurance coverage and availability for the two new pills are still settling out as adoption grows, and market forecasts, while widely cited by the pharmaceutical industry, are projections rather than guarantees.

What happens next

Several more GLP-1-class drugs are moving through late-stage trials. Novo Nordisk filed for approval of CagriSema, a combination injectable, on December 18, 2025, with a decision expected around late 2026 ^[2]. Lilly's triple-hormone drug retatrutide showed about 28.3% weight loss in Phase 3 data released in May 2026, the strongest result reported so far among this drug class, though it remains unapproved ^[2]. Analysts expect North America to keep its lead through 2034, even as Asia Pacific is projected to grow fastest, at roughly 42.6% annually ^[1].